INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
INNOVENT BIO: LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
INNOVENT BIO: CHANGE IN COMPOSITION OF BOARD COMMITTEES
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVED CHINA'S FIRST KRAS G12C INHIBITOR DUPERT
INNOVENT BIO: INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THESECOND QUARTER OF 2024
INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATIONACCEPTED THE NEW DRUG APPLICATION OF MAZDUTIDEFOR TYPE 2 DIABETES
INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
INNOVENT BIO: Amended and Restated Memorandum and Articles of Association
INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
INNOVENT BIO: Form of Proxy for use at the Extraordinary General Meeting to be held onFriday, June 21, 2024
INNOVENT BIO: Form of Proxy for use at the Annual General Meeting to be held onFriday, June 21, 2024
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT -THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTEDTHE NEW DRUG APPLICATION FOR IBI311 (IGF-1R ANTIBODY) FORTHYROID EYE DISEASE
INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
INNOVENT BIO: LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
INNOVENT BIO: APPOINTMENT OF DIRECTORSANDCHANGE IN COMPOSITION OF BOARD COMMITTEES
INNOVENT BIO: INSIDE INFORMATION ANNOUNCEMENT -UPDATE ON THE COMPANY''S PRODUCT REVENUE IN THEFIRST QUARTER OF 2024
INNOVENT BIO: 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTEDTHE NEW DRUG APPLICATION ANDGRANTED PRIORITY REVIEW DESIGNATIONFOR SINTILIMAB COMBINATION WITH FRUQUINTINIBFOR THE TREATMENT OF ADVANCED ENDOMETRIAL CANCER
No Data